CD274 and head and neck squamous cell carcinoma: In patients with SCCHN (CheckMate 141), a lower prevalence of PD-L1–positive patients was seen with AI-powered scoring (42.5% and 28.8%) compared with manual scoring (54.9% and 34.0%) at cutoffs of ≥1% and ≥5%, respectively, though the difference was not significant (Table 1).